Rates and predictors of attrition among children on antiretroviral therapy in Ethiopia: A prospective cohort study

Mulatu Biru, Inger Hallström, Pia Lundqvist, Degu Jerene, Mulatu Biru, Inger Hallström, Pia Lundqvist, Degu Jerene

Abstract

Introduction: Attrition from antiretroviral therapy (ART) programmes is a critical challenge among children receiving care in resource-limited settings. Our objective was to determine the rates and predictors of attrition among children on ART in Ethiopia.

Methods: Between December 2014 and September 2016, we conducted a prospective cohort study in eight health facilities in Ethiopia. Eligibility criteria included age 3 months-14 years; being on ART for not more than a month. Outcome was attrition due to death and/or loss to follow-up. Predictor variables were child clinical and socio-demographic characteristics, and caregiver socio-demographic characteristics. We used Cox Regression analyses to examine the association between predictors and outcome.

Results: Of 309 children, 304 were included, 52% were male. Their median age was 9 years (Inter-quartile range, IQR, 6-12). At ART initiation, their median CD4 was 362 cells/mm3 (IQR 231-499); and 74.3% had WHO stage 1 or 2 disease. During 287.7 person-years of observation (PYO), 24 attritions were recorded, yielding an attrition rate of 8.3 per 100 PYO (95% CI 5.4-12.1). Of these, six children were reported dead, leading to a mortality rate of 2.1 per 100 PYO (95% CI 0.8-4.3). Eighteen were lost to follow-up (LTFU) leading to LTFU rate of 6.26 per 100 PYO (95% CI: 3.83-9.70). The majority, 14 (58%) of attrition occurred during the first six months of treatment. Age below three years [aHR] = 5.14 (95% CI: 2.07-12.96), rural residence (aHR = 3.97, 95% CI: 1.34-11.78) and baseline Hgb in g/dl < 10 g/dl [aHR] = 5.68 (95% CI: 2.03-6.23) predicted higher risk of attrition. Baseline Hgb < 10 g/dl (aHR = 16.63, 95% CI: 1.64-168.4) and WHO stage III or IV (aHR = 12.25, 95% CI: 1.26-119.05) predicted the death of the child. Higher attrition was documented among children of both biological parents alive and biologically related close family caregivers.

Conclusion: Younger children, those from rural areas, and children with anaemia were at higher risk of attrition, especially during the early months of treatment, and therefore should be prioritized during treatment follow-up. Further studies should examine underlying reasons for higher attrition.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flow chart showing the cohort…
Fig 1. Flow chart showing the cohort profile.
Fig 2. Cumulative incidence and survival curve…
Fig 2. Cumulative incidence and survival curve of recorded attrition.
A) Cumulative incidence by child age group, B) Cumulative incidence by child baseline Hgb, C) Survival curve by child age group and D) Survival curve by child baseline Hgb.

References

    1. UNAIDS. On the Fast-Track to end AIDS. 2016.
    1. UNICEF. For every child, end aids: seventh stocktaking report. UNICEF Data: Monitoring the Situation of Children and Women. 2016.
    1. Federal Ministry of Health E. Guidelines for Paediatric HIV/AIDS Care and Treatment in Ethiopia. 2007.
    1. FHAPCO. HIV/AIDS STRATEGIC PLAN 2015–2020 IN AN INVESTMENT CASE APPROACH. 2014.
    1. Federal Ministry of Health E. Accelerated action plan for improving pediatric HIV treatment, care and support in Ethiopia. Federal ministry of health. 2013.
    1. Federal Ministry of Health E. Supplement to the 2014 National Comprehensive HIV Prevention, Care and Treatment Guidline of Ethiopia to address the HIV test and Start. 2016.
    1. World; Health Organization (WHO). Prevent HIV, test and treat all—WHO support for country impact Progress report. World Health Organization; 2016.
    1. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2016;(Ed. 2).
    1. Abuogi LL, Smith C, McFarland EJ. Retention of HIV-Infected Children in the First 12 Months of Anti-Retroviral Therapy and Predictors of Attrition in Resource Limited Settings: A Systematic Review. PloS one. 2016;11(6):e0156506 Epub 2016/06/10. doi: .
    1. Melaku Z, Lulseged S, Wang C, Lamb MR, Gutema Y, Teasdale CA, et al. Outcomes among HIV-infected children initiating HIV care and antiretroviral treatment in Ethiopia. Tropical medicine & international health: TM & IH. 2017. Epub 2017/01/10. doi: .
    1. Wilhelmson S, Reepalu A, Tolera Balcha T, Jarso G, Bjorkman P. Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic. Global health action. 2016;9(1):29943 Epub 2017/02/06. doi:
    1. Koye DN, Ayele TA, Zeleke BM. Predictors of mortality among children on Antiretroviral Therapy at a referral hospital, Northwest Ethiopia: a retrospective follow up study. BMC pediatrics. 2012;12:161 Epub 2012/10/10. doi: .
    1. Asfawesen GY, Solomie J, Bisirat T, Berhanu GM, Mebratu B, Rahlenbeck S. Outcome in a paediatric cohort receiving ART in Addis Abeba, Ethiopia. Acta paediatrica (Oslo, Norway: 1992). 2011;100(8):1164–7. Epub 2011/03/01. doi: .
    1. Biru M, Jerene D, Lundqvist P, Molla M, Abebe W, Hallstrom I. Caregiver-reported antiretroviral therapy non-adherence during the first week and after a month of treatment initiation among children diagnosed with HIV in Ethiopia. 2016;(1360–0451.
    1. CSA E. Population Projection of Ethiopia for All Regions At Wereda Level from 2014–2017. Central Statistical Agency of Ethiopia; 2013.
    1. Federal Ministry of Health (FMOH). Unpublished, compiled database June, 2017.
    1. World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. 2011. Geneva: WHO Google Scholar. 2015.
    1. World Health Organization (WHO). WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007.
    1. WMA. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013;310(20):2191–4. Epub 2013/10/22. doi: .
    1. Alvarez-Uria G, Naik PK, Midde M, Pakam R. Predictors of loss to follow-up after engagement in care of HIV-infected children ineligible for antiretroviral therapy in an HIV cohort study in India. Germs. 2014;4(1):9–15. Epub 2014/03/19.
    1. Hagstromer O, Lundstedt L, Balcha TT, Bjorkman P. Decentralised paediatric HIV care in Ethiopia: a comparison between outcomes of patients managed in health centres and in a hospital clinic. Global health action. 2013;6:22274 Epub 2013/11/14. doi: .
    1. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2013.
    1. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2016;(Ed. 2).
    1. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. The Lancet Infectious diseases. 2008;8(8):477–89. Epub 2008/07/26. doi: .

Source: PubMed

3
订阅